Evidence map›Paper›PMID 41275454›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Real-world application of

Shuting Li, Yizhao Xie, Cheng Liu, Shaoli Song, Hongxia Wang, Zhongyi Yang, Biyun Wang

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shuting Li *Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Yizhao Xie *Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Cheng Liu *Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Shaoli SongDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Hongxia WangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Zhongyi YangDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. yangzhongyi21@163.com.ORCID 0000-0001-6195-9942
Biyun WangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. wangbiyun0107@hotmail.com.ORCID 0000-0002-7829-1544

Funding

Beijing Science and Technology Innovation Medical Development Foundation KC2022-ZZ-0091-4Beijing Xisike Clinical Oncology Research Foundation Y-2022HER2AZQN-0378Beijing Xisike Clinical Oncology Research Foundation Y-Young2022-0286National Natural Science Foundation of China 82102722National Natural Science Foundation of China 82373340
6 · The paper itself

Abstract

background

methodsWe retrospectively screened 1049 patients who underwent

resultsAmong the 23 patients, 7 (30.4%) developed intracranial symptoms, 12 (52.2%) received radiotherapy or surgery, and 16 (69.6%) received endocrine-based systemic therapy. FES-PET showed 80% concordance with MRI and 100% with pathology. Patients with the high maximum standardized uptake value (SUVmax) (≥ 1.8) demonstrated a markedly prolonged intracranial PFS compared to those with lower values (mPFS not reached vs 3.75 months, p < 0.001). ROC curve analysis established FES SUVmax as a significant predictor of intracranial progression (AUC = 0.742; 95% CI, 0.556-0.928). Multivariate analysis further identified FES SUVmax classification (HR = 7.985, 95% CI 1.214-52.506, p = 0.031) and disease-free interval (DFI) (HR = 0.033, 95% CI 0.005-0.211, p < 0.001) as the significant, independent predictors of intracranial PFS.

conclusionOur results confirm the vital role of

Indexed as

Brain NeoplasmsBreast NeoplasmsEstradiolPositron Emission Tomography Computed TomographyAdultAgedFemaleHumansMiddle AgedReceptors, EstrogenRetrospective Studies16-fluoroestradiolEstradiolReceptors, Estrogen18F-fluoroestradiol positron emission tomography/computed tomographyBrain metastasesBreast cancer

Identifiers

PMID41275454

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.